Search
Menu

Detecting early-stage Lyme

Facebook X LinkedIn Email
DOUGLAS FARMER, SENIOR EDITOR [email protected]

DOUGLAS FARMER, SENIOR EDITORLyme disease continues to infect a large swath of the population in North America. The reliance on the standard two-tiered serodiagnostic test to identify its presence has proved problematic because the bacteria that cause the disease — Borrelia burgdorferi — can be difficult to trace in the early stages. Some in the biomedical community are pinning their hopes for reliable testing on the photonics technologies found in chip-based assays and used to measure effects such as fluorescence and absorption.

The Tick-Borne Disease Working Group has placed this pursuit of reliable testing in a national context with its recent report to the U.S. Congress. The group estimates that tick-borne diseases in general — and Lyme in particular — are vastly underestimated in national statistics, and that incidences are potentially 8 to 12× higher than officially diagnosed. The need for reliable point-of-care diagnostic testing will only grow as the true infection rate comes into focus.

As I discuss in my cover story in this edition of BioPhotonics, researchers at institutions across the country are busy looking for light-based effects that can be produced when proteins in Lyme bacteria are present. The scientists are using gold nanoparticles to measure a colorimetric response — plasmonic fluorescence — and also the corresponding absorption. Others are utilizing microfluidics to identify the bacteria in the early stages of the disease. While commercialization of these concepts may be a few years away, studies involving a broad segment of the population are proceeding. Learn more here.

Another new technology for detecting and diagnosing conditions in the body is the subject of a feature by Jianglai Wu, Na Ji, and Kevin Tsia. These researchers developed a technique called free-space angular-chirp-enhanced delay (FACED), which generates a series of receding virtual images that can capture high-speed cellular processes via a module that can be attached to any standard microscope. Read more about this development here.


Elsewhere in this edition, Adam Glaser and Melissa Haahr write about a team of researchers that is using a form of light sheet microscopy to overcome the historical limitations of pathological analysis. The group has created open-top light-sheet microscopes, which place optical components below the specimen, allowing for the illumination of samples of varying sizes. Explore their efforts here.

Meanwhile, Sulayman Oladepo expounds on the invention of a smart probe that is based on a string of nucleic acids. The probe absorbs fluorescent dyes, revealing a variety of biomarkers, including those intrinsic to cancer. The probe is used to analyze micro-RNA that is linked to a cancer biomarker. Follow Oladepo’s research journey, which begins here.

And in “Biopinion,” the Forever Healthy Foundation discusses the benefits of low-level light therapy, a form of photobiomodulation. The foundation’s analysis verifies that light in the red and infrared regions can stimulate the skin and create a more youthful appearance. Read more about this topic here.

Enjoy the issue!


Published: May 2021
Editorial

We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.